A new murine model to study Pso and PsA! Immunodeficient mice NSG-SGM3 🐁 injected w/ serum & PBMCs from Pso and/or PsA pts = pro & arthritis (same phenotype than pts) Mice skin & synovia >effector memory CD8 T cell & < naïve https://t.co/cxSvEZC9Ly Abs#L04 #ACR22 @Rheumnow https://t.co/hfbtSsP3f8

• Psoriatic Arthritis Disease Subtypes Mediated by CD8 T Cells Are Phenocopied in…

#L02 #acr22 @rheumnow Bimekizumab ph3 in PsA: meaningful clinical improvement, improved mTSS, no new safety signals. Wk 52 ACR50: 53.0% PBO/BKZ, 54.5% BKZ, 50.0% ADA; MDA 53.7% PBO/BKZ, 55.0% BKZ, 52.9% ADA . mTSS change from baseline ≤0.5): 87.3% PBO/BKZ, 89.3% BKZ, 94.1% ADA https://t.co/NYRrPUBjt1

BE OPTIMAL: BKZ in PsA Phase 3 RCT Data at 52 wks 700+ completed study ACR50: 53% PBO/BKZ, 54% BKZ, 50% ADA PASI 100 65% PBO/BKZ, 61% BKZ, 48% ADA No Rx progression 87% PBO/BKZ, 89% BKZ, 94% ADA Candida infections 7% BKZ, 0.7% ADA https://t.co/MMjN1Aa3qf Abs#L02 #ACR22 @Rheumnow https://t.co/keF0QOZMwA

• Bimekizumab Treatment in Biologic DMARD-Naïve Patients with Active Psoriatic Ar…

Get the skinny on Bimmy! Gotta learn this name #Bimekizumab in bio naive PsA N=852 Bimmy=IL17 A & F inhibitor Great data on skin & joints. Where will it fit in as we have other IL17Ai’s is IL17F giving added value? #ACR22 #ACRBest @RheumNow https://t.co/wNAzTaLhsM

Does tofacitinib work better in patients with PsA and AS who smoke? Abstract #1036 #ACR22 @RheumNow 🚬519 ever smokers 🚭767 never smokers 💉In PsA only, TOF efficacy was greater in ever smokers vs. PBO ✋Overall, efficacy was generally comparable in ever v. never 🚬

Here's the 1 year model #ACR22 @RheumNow https://t.co/VhEuJMMyIt

Eder et al. New PRESTO prediction model for PsA development in PsO. 1 year and 5 year models presented @RheumNow #ACR22 Abstr#1612 https://t.co/xMMVaIGnN5 https://t.co/RlJ3ZlEeDE

• Prediction of Psoriatic Arthritis Tool (PRESTO): Development and Performance of…